抗EGFR 单抗治疗局部晚期头颈部鳞状细胞癌临床共识(2023 年版)
许婷婷， 胡超苏， 李宝生 - 中国癌症杂志, 2023 - china-oncology.com
… Head Neck, 2022, 44(3): 749-759. … The KRASvariant and cetuximab response in head and
neck squamous cell cancer: a secondary analysis of a randomized clinical trial[J]. JAMA Oncol…
neck squamous cell cancer: a secondary analysis of a randomized clinical trial[J]. JAMA Oncol…
[PDF][PDF] 晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析
郭伟 - 口腔颌面外科杂志, 2012 - journal06.magtech.org.cn
… of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell
carcinoma of the head and neck … Arch Otolaryngol Head Neck Surg, 2008,134(4):355r362 [33] …
carcinoma of the head and neck … Arch Otolaryngol Head Neck Surg, 2008,134(4):355r362 [33] …
Dasatinib 在頭頸癌的藥理機轉研究
YC Lin - 2014 - ntur.lib.ntu.edu.tw
… 受體的單株抗體cetuximab在頭頸癌成功的展現療效;儘管如此,cetuximab的效果仍然有限,頭頸
癌… apoptosis of head and neck squamous cell carcinoma (HNSCC) cells was investigated in …
癌… apoptosis of head and neck squamous cell carcinoma (HNSCC) cells was investigated in …
[HTML][HTML] 替雷利珠单抗单药治疗复发或转移性头颈部鳞状细胞癌
宋攀， 梁发雅， 叶煜初， 黄永胜， 伍韬玮… - … Head and Neck …, 2023 - ncbi.nlm.nih.gov
… Six patients with recurrent/metastatic head and neck squamous cell carcinoma who received
tislelizumab monotherapy in our hospital from 2018 to 2020 were retrospectively analyzed. …
tislelizumab monotherapy in our hospital from 2018 to 2020 were retrospectively analyzed. …
化疗在头颈鳞状细胞癌功能保全策略的研究进展
尹高菲， 郭伟， 陈晓红， 黄志刚 - 国际耳鼻咽喉头颈外科杂志, 2019 - entbjb.com
… head and neck squamous cell carcinoma. [Key words] Head and Neck Neoplasms; Carcinoma,
Squamous Cell; … cisplatin and cetuximab in unresectable squamous cell carcinoma of the …
Squamous Cell; … cisplatin and cetuximab in unresectable squamous cell carcinoma of the …
头颈鳞状细胞癌人乳头状瘤病毒检测进展
冯守昊， 徐伟 - 国际耳鼻咽喉头颈外科杂志, 2018 - entbjb.com
… [摘要] 不同部位的头颈鳞状细胞癌(squamous cell carcinoma of the head and neck, SCCHN)…
More on severe cutaneous reaction with radiotherapy and cetuximab[J]. N Engl J Med, 2007…
More on severe cutaneous reaction with radiotherapy and cetuximab[J]. N Engl J Med, 2007…
[HTML][HTML] HPV 阳性口咽癌的诊疗新进展
刘雅岷， 陈怀宏 - … of Clinical Otorhinolaryngology, Head, and Neck …, 2022 - ncbi.nlm.nih.gov
… 研究中5%~20%的口咽鳞状细胞癌(oropharyngeal squamous cell carcinoma，OPSCC)中，HPV …
in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis. Int J …
in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis. Int J …
[HTML][HTML] 新辅助免疫联合化疗在局晚期下咽鳞癌喉器官保留治疗中的意义
吴晋， 胡国华， 李旻珉， 王志海， 马玮… - … , Head, and Neck …, 2023 - ncbi.nlm.nih.gov
… 靶向程序性死亡受体1(programmed cell death protein 1，PD-1)通路的ICIs已被批准用于一线
的复发和转移性(R/M)头颈鳞癌(head and neck squamous cell carcinoma，HNSCC)患者。免疫…
的复发和转移性(R/M)头颈鳞癌(head and neck squamous cell carcinoma，HNSCC)患者。免疫…
表皮生长因子受体在人头颈部鳞状细胞癌中的作用研究进展
李召卿， 周旋， 张仑 - 中国肿瘤临床, 2018 - cjco.cn
… 摘要头颈部鳞状细胞癌(head and neck squamous cell carcinoma,HNSCC)是常见的恶性肿瘤
,… binding domain confers increased sensitivity to cetuximab in head and neck cancer[J]. Eur J …
,… binding domain confers increased sensitivity to cetuximab in head and neck cancer[J]. Eur J …
头颈部肿瘤的免疫治疗
郭晔 - 中国癌症杂志, 2017 - china-oncology.com
… of head and neck cancer is head and neck squamous cell … /or metastatic head and neck
squamous cell carcinoma: results … - and cetuximab-refractory head and neck cancer: results from …
squamous cell carcinoma: results … - and cetuximab-refractory head and neck cancer: results from …